Osimertinib also improves overall survival in EGFR-mutated NSCLC

被引：0
|
作者：
Lichert, Frank
机构：
来源：
PNEUMOLOGIE | 2024年 / 78卷 / 03期
关键词：
D O I：
10.1055/a-2196-8365
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Innerhalb der Studie ADAURA hatte eine adjuvante Osimertinib-Therapie bei Patienten mit nicht kleinzelligem Lungenkarzinom (NSCLC) der Stadien IB-IIIA und EGFR-Mutation gegenuber Placebo ein signifikant langeres krankheitsfreies uberleben zu Folge. Nun wurden die Ergebnisse einer finalen Analyse zum Gesamtuberleben vorgestellt.
引用
收藏
页码：143 / 143
页数：1
相关论文
共 50 条
  • [21] Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
    Zheng, Mei-Mei
    Li, Yang-Si
    Tu, Hai-Yan
    Sun, Hao
    Yin, Kai
    Jiang, Ben-Yuan
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhou, Qing
    Xu, Chong-Rui
    Wang, Zhen
    Chen, Hua-Jun
    Zhou, De-Xiang
    Wu, Yi-Long
    BMC MEDICINE, 2022, 20 (01)
  • [22] Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
    Buder, A.
    Hochmair, M. J.
    Setinek, U.
    Filipits, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] Osimertinib in EGFR-Mutated Lung Cancer REPLY
    Herbst, Roy S.
    Wu, Yi-Long
    Tsuboi, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 676
  • [24] Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
    Crowley, Fionnuala
    Fitzgerald, Bailey G.
    Bhardwaj, Aarti S.
    Siraj, Irine
    Smith, Cardinale
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):
  • [25] Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis
    Yi, Lilan
    Fan, Junsheng
    Qian, Ruolan
    Luo, Peng
    Zhang, Jian
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (01) : 284 - 294
  • [26] PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC
    Vokes, Natalie I.
    Le, Xiuning
    Yap, Timothy A.
    CLINICAL CANCER RESEARCH, 2024, 30 (18) : 3968 - 3970
  • [27] Prognostic impact of bone metastases in osimertinib-treated patients with EGFR-mutated NSCLC
    Tanaka, Ichidai
    Gen, Soei
    Hori, Kazumi
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Ishii, Makoto
    CANCER SCIENCE, 2025, 116 : 329 - 329
  • [28] Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
    de Jager, Vincent D.
    Stigt, Jos A.
    Niemantsverdriet, Maarten
    ter Elst, Arja
    van der Wekken, Anthonie J.
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [29] Gefitinib Approved for EGFR-Mutated NSCLC
    不详
    CANCER DISCOVERY, 2015, 5 (09) : 896 - 896
  • [30] Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
    Liao, B. -C.
    Yang, C. -Y.
    Tsai, T. -H.
    Liao, W. -Y.
    Chen, K. -Y.
    Ho, C. -C.
    Shih, J. -Y.
    Yu, C. -J.
    Yang, J. C. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S463 - S463
12345